Global Collaboration:

Changing the Face of Pandemic Research



John C. Marshall MD FRCSC Japanese Society of Intensive Care Medicine



St. Michael's Hospital

February 13, 2021

University of Toronto



Comment

InFACT: a global critical care research response to H1N1

The H1N1 pandemic presents acute care researchers with an extraordinary challenge and an unprecedented opportunity. By early October, 2009, there had been more than 340 000 reported cases of H1N1 infection in 191 countries, with more than 4100 deaths.¹ WHO initially projected that up to 2 billion people could become infected with the virus over the next 2 years.² Although vaccination programmes and other factors should reduce this number, plausible estimates of the number of infected individuals who might benefit from admission to intensive care range from 200000 to 10 million. Influenza killed at least 50 million people during the 1918 pandemic.3 Today, with antibiotics and antiviral agents, mechanical ventilation, and the supportive measures available in intensive care, most of those deaths could have been prevented.

and treatment of severe H1N1 disease. In parallel, we will develop a biobank to facilitate studies of genetic susceptibility and clinical biology.

We are starting a programme of collaborative, investigator-led randomised trials of treatment strategies that target both the virus and the host response. Our initial three studies will evaluate inexpensive interventions that are available in both the developed and the developing world: corticosteroids and statins. They use adaptive designs to ensure that results can be quickly incorporated into practice, and that ineffective treatments are dropped. As measures of efficacy, they will measure survival of individual patients and the rapidity with which patients can be liberated from limited intensive-care resources.

We seek to reduce the consequences of severe H1N1 infection in the developed world, where available



Published Online November 10, 2009 DOI:10.1016/S0140-6736(09)61792-X

- Lancet 375:11, 2010

Intensive Care Med (2012) 38:29–39 DOI 10.1007/s00134-011-2409-8

SPECIAL ARTICLE

Djillali Annane Marion Antona Blandine Lehmann Cecile Kedzia Sylvie Chevret the CORTIFLU Investigators and the CRICs, AZUREA, and REVA/SRLF networks

Designing and conducting a randomized trial for pandemic critical illness: the 2009 H1N1 influenza pandemic

	What was done?	How long did it take?	How could it be better?	Estimated time saving
Initiative	Investigators led trial	About 4 weeks	Investigators networks should be prepared in advance to launch future pandemic research	4 weeks
Scientific evaluation of the protocol	Independent evaluation by Institute of Microbiology and Infectious Diseases (part of INSERM)	4 weeks' fast-track process	Scientific evaluation should have been anticipated Reviews should have taken no longer than 1 week	3 weeks
Financial evaluation and sponsoring	Independent evaluation by Department for Clinical Research and Development (AP-HP)	3 days' fast-track process	Unlikely to be shorter	-
Ethical evaluation	Independent evaluation by Comité de Protection des Personnes Saint Germain en Laye	3 weeks' fast-track process	Ethical evaluation should have been anticipated Reviews should have taken no longer than 1 week Ethical evaluation should have been run in parallel to the scientific evaluation	3 weeks
Study treatments	Centralized preparation of active treatment and placebo and labeling	6 weeks' fast-track process	Local preparation of active treatment and placebo using commercially available drugs	5 weeks
Activation of study sites	Study materials and drugs were shipped via express mail and conference calls were organized to review all study materials with local investigators and pharmacists 39 sites were activated in 3 consecutive waves	3 weeks	All sites should be activated in one single wave Conference calls worked very well	2 weeks
Assistance for workload associated with patients enrolment	We provided the investigators with technical assistance for completing electronic CRF	-	A dedicated research team should be provided to each study site	-

Home > Search Results							
Modify Search Start Over							+
				238 Studies found for: H1N1			
List By Topic On Map	Se	arch D	etails				
Hide Filters							ad Subscribe to RSS
liters	Showin	ıg: 1-10	of 238 stud	lies 10 → studies per page			Show/Hide Columns
Apply Clear	Row	Saved	Status	Study Title	Conditions	Interventions	Locations
	1		Terminated	Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot	 H1N1 Influenza 	Drug: Rosuvastatin or identical	St. Michael's Hospital
Status 🗕				Trial	muenza	placeboDrug: Placebo	Toronto, Ontario, Canada
Recruitment 🚯 :	2		Completed	Study of the Safety and Immunogenicity of H1N1	• H1N1 Flu	Biological: HAC1 Vaccine	Walter Reed Army
Not yet recruiting		_		Vaccine			Institute of Research
Recruiting							(WRAIR)
Enrolling by invitation							Silver Spring, Maryland, United States
□ Active, not recruiting							
Suspended Terminated	3		Unknown †	Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation	 H1N1 Influenza 		Hadassah Medical Organization

H1N1 Influenza 238 studies





			ional Library Trials.g		Find Studies •	 About Studies ▼ S 	Submit Studie	s ▼ Resources ▼ About Site	e ▼ PRS Login		
	Home >	Searc	h Results								
	Modify	Search	Start Ove	<u>r</u>					(+]	
List By Topic On Ma		e searche	ed for COVID a	es found for: COVID-19 and SARS-CoV-2. <u>See Search Deta</u>		• Clinical Trials • WHO Trial Re • NIH: COVID-1	it clinical studi .gov: <u>Federal</u> egistry Netwo 9 Treatment (included: COVID-19 ies related to COVID-19: ly-funded clinical studies related to (rk : <u>COVID-19 studies from the ICTF</u> <u>Guidelines</u> <u>f Listed COVID-19 Studies (Beta)</u>			
Hide Filters	Showir	ng: 1-10	of 4,737 studie	es 10 🗸 studies per page					ų	Download	Show/Hide Columns
Apply Clear	Row	Saved	Status	s	Study Title		Conditions	Interventions		Locations	
atus ecruitment 🔁 :	1		Recruiting	Duvelisib to Combat COVID-19			COVID-19	 Drug: Duvelisib Procedure: Peripheral blood draw Drug: Placebo 	 Missouri Baptist Me Saint Louis, Missou Washington Univer Saint Louis, Missou 	iri, United States sity School of Me	dicine
) Not yet recruiting) Recruiting) Enrolling by invitation	2		Recruiting	Observational Cohort of COVID-19 Patie			COVID-19		Department of Infer APHP Garches, France		
Active, not recruiting	3		Enrolling by	Estimation of Dynamics of Humoral and	Cellular Immunit	y in COVID-19 Patients	Covid19	Diagnostic Test: Humoral and cellular	Institute of Biophys	ics and Cell Eng	ineering of National

COVID-19 4737 Studies 106 Countries

Why do we need research during a pandemic?

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury


The 2019 novel coronavirus (2019-nCoV) outbreak is a major challenge for clinicians. The clinical course of patients remains to be fully characterised, little data are available that describe the disease pathogenesis, and no pharmacological therapies of proven efficacy yet exist.

Corticosteroids were widely used during the outbreaks of severe acute respiratory syndrome (SARS)- CoV^1 and

Middle East respiratory syndrome (MERS)-CoV,² and are being used in patients with 2019-nCoV in addition to other therapeutics.³ However, current interim guidance from WHO on clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected (released Jan 28, 2020) advises against the use of corticosteroids unless indicated for

Published Online February 6, 2020 https://doi.org/10.1016/ S0140-6736(20)30317-2


www.thelancet.com Vol 395 February 15, 2020





ORIGINAL ARTICLE


Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

The RECOVERY Collaborative Group*










Coagulopathy in COVID-19





Pre-publication interim data, not from a locked database and not peer reviewed

ATTACC, REMAP-CAP, and ACTIV IV-4a mpRCT Primary outcome


State & D-dimer Strata	Proportional Odds Ratio Median (95% Crl)	Trial Statistical Conclusion
Moderate state, low D-dimer	1.57 (1.14 - 2.19)	Superiority [Probability of OR>1 = 0.997]
Moderate state, high D-dimer	1.53 (1.09 - 2.17)	Superiority [Probability of OR>1 = 0.991]
Moderate state, missing D-dimer	1.51 (1.06 – 2.15)	n/a [™]
Severe state	0.76 (0.60 – 0.97)	Futility* [Probability of OR>1.2 < 0.001]

* Posterior probability of inferiority [Probability of OR<1 = 0.985]

 $\overline{\Delta}$ Not evaluated for stopping at interim

OR >1 represents benefit. A higher OR occurs when either mortality is improved and/or if those who survive have reduced requirement for organ support

Release date: January 28, 20



How is COVID-19 Changing Clinical Research?

New Trial Designs: The Platform Trial

- Evaluates multiple interventions
- Can add new interventions
- Provides sites with flexibility
- Can evaluate drug-drug interactions
- Provides immediate uptake of findings



Colchicine

- Regeneron antibody cocktail
- Baricitinib
- Aspirin



Home About REMAP-CAP COVID-19 The REMAP-CAP Team Resources Contact Us

REMAP-CAP

A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia



Patient randomisations

10,333

Patient randomisations with suspected or proven COVID-19

31

Available interventions in 12 Domains


6,195

Total patients

5,388

Patients with suspected or proven COVID-19 296

Active Sites



New Models of Collaboration


- Amongst specialties
- Across countries
- Amongst funders
- Across studies
- By large teams



- 12000 patients
- 500 sites

• Pragmatic, decentralized

BINFACT



Determinants of Citation Impact in Large Clinical Trials in Critical Care: The Role of Investigator-Led Clinical Trials Groups*

John C. Marshall, MD¹; Wilson Kwong, MSc^{1,2}; Kamya Kommaraju, BSc¹; Karen E. A. Burns, MD, MSc¹

TABLE 5. The Impact of Organizational Model on Median Annual Citation Rates

Model	No. of Trials (%)	Median (IQR) Annual Citations
Industry led	85 (21.7)	12.3 (5.4–24.1)
Investigator led		
Single center	114 (29.2)	7.0 (3.5–12.9)
2–5 centers	59 (15.1)	11.0 (4.5–22.4)
Multicentre ad hoc group	88 (22.5)	19.1 (9.8–30.4)
Multicentre trials group	45 (11.5)	45.7 (17.3–86.2) ^{a,b}
IQR = interquartile range. p < 0.0001, Kruskal-Wallis. p < 0.0001 vs ad hoc group.		

Crit Care Med 44:663, 2016



The Multiplatform RCT

ATTACC, REMAP, and ACTIV IV (NIH) An international multiplatform RCT (mpRCT)

- Update:
 - December 18th, DSMB recommending stopping the severe state
 - ~1200 enrolled. Interim efficacy based on ~600 patients
- Moderate state continues ~2000 patients enrolled

JAMA | Original Investigation | CARING FOR THE CRITICALLY ILL PATIENT

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically III Patients With COVID-19 A Meta-analysis

The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group

Drug and trial identifier administration Steroids No steroids (95% Cl) steroids steroids Dexamethasone DEXA-COVID 19 NCT04325061 High: 20 mg/d intravenously 2/7 2/12 2.00 (0.21-18.69) (0.21		ClinicalTrials.gov	Initial dose and	No. of de No. of pa	aths/total tients	Odds ratio	Favors	Favors no	Weight,
DEXA-COVID 19 NCT04325061 High: 20 mg/d intravenously 2/7 2/12 2.00 (0.21-18.69) CODEX NCT04327401 High: 20 mg/d intravenously 69/128 76/128 0.80 (0.49-1.31) RECOVERY NCT04381936 Low: 6 mg/d orally or intravenously 95/324 283/683 0.59 (0.44-0.78) Subgroup fixed effect 166/459 361/823 0.64 (0.50-0.82) Hydrocortisone	rug and trial	identifier	administration	Steroids	No steroids	(95% CI)	steroids	steroids	%
CoDEX NCT04327401 High: 20 mg/d intravenously 69/128 76/128 0.80 (0.49-1.31) RECOVERY NCT04381936 Low: 6 mg/d orally or intravenously 95/324 283/683 0.59 (0.44-0.78) Subgroup fixed effect 166/459 361/823 0.64 (0.50-0.82) Hydrocortisone	examethasone								
RECOVERY NCT04381936 Low: 6 mg/d orally or intravenously 95/324 283/683 0.59 (0.44-0.78) Subgroup fixed effect 166/459 361/823 0.64 (0.50-0.82) Hydrocortisone	DEXA-COVID 19	NCT04325061	High: 20 mg/d intravenously	2/7	2/12	2.00 (0.21-18.69)	İ	• • •	0.92
Subgroup fixed effect 166/459 361/823 0.64 (0.50-0.82) Hydrocortisone CAPE COVID NCT02517489 Low: 200 mg/d intravenously 11/75 20/73 0.46 (0.20-1.04) COVID STEROID NCT04348305 Low: 200 mg/d intravenously 6/15 2/14 4.00 (0.65-24.66) REMAP-CAP NCT02735707 Low: 50 mg every 6 h intravenously 26/105 29/92 0.71 (0.38-1.33) Subgroup fixed effect 43/195 51/179 0.69 (0.43-1.12) Methylprednisolone Steroids-SARI NCT04244591 High: 40 mg every 12 h intravenously 13/24 13/23 0.91 (0.29-2.87) Overall (fixed effect) 222/678 425/1025 0.66 (0.53-0.82) Image: Comparison of the terogeneity; l ² = 15.6% Image: Comparison of the terogeneity; l ² = 15.6%	CoDEX	NCT04327401	High: 20 mg/d intravenously	69/128	76/128	0.80 (0.49-1.31)			18.69
Hydrocortisone CAPE COVID NCT02517489 Low: 200 mg/d intravenously 11/75 20/73 0.46 (0.20-1.04) COVID STEROID NCT04348305 Low: 200 mg/d intravenously 6/15 2/14 4.00 (0.65-24.66) REMAP-CAP NCT02735707 Low: 50 mg every 6 h intravenously 26/105 29/92 0.71 (0.38-1.33) Subgroup fixed effect 43/195 51/179 0.69 (0.43-1.12) Methylprednisolone	RECOVERY	NCT04381936	Low: 6 mg/d orally or intravenously	95/324	283/683	0.59 (0.44-0.78)			57.00
CAPE COVID NCT02517489 Low: 200 mg/d intravenously 11/75 20/73 0.46 (0.20-1.04) COVID STEROID NCT04348305 Low: 200 mg/d intravenously 6/15 2/14 4.00 (0.65-24.66) REMAP-CAP NCT02735707 Low: 50 mg every 6 h intravenously 26/105 29/92 0.71 (0.38-1.33) Subgroup fixed effect 43/195 51/179 0.69 (0.43-1.12) Methylprednisolone	Subgroup fixed e	ffect		166/459	361/823	0.64 (0.50-0.82)			76.60
COVID STEROID NCT04348305 Low: 200 mg/d intravenously $6/15$ $2/14$ $4.00 (0.65-24.66)$ REMAP-CAP NCT02735707 Low: 50 mg every 6 h intravenously $26/105$ $29/92$ $0.71 (0.38-1.33)$ Subgroup fixed effect 43/195 $51/179$ $0.69 (0.43-1.12)$ Methylprednisolone Steroids-SARI NCT04244591 High: 40 mg every 12 h intravenously $13/24$ $13/23$ $0.91 (0.29-2.87)$ Overall (fixed effect) $222/678$ $425/1025$ $0.66 (0.53-0.82)$ $425/1025$ $0.66 (0.53-0.82)$	lydrocortisone								
REMAP-CAP NCT02735707 Low: 50 mg every 6 h intravenously 26/105 29/92 0.71 (0.38-1.33) Subgroup fixed effect 43/195 51/179 0.69 (0.43-1.12) Methylprednisolone 5teroids-SARI NCT04244591 High: 40 mg every 12 h intravenously 13/24 13/23 0.91 (0.29-2.87) Overall (fixed effect) 222/678 425/1025 0.66 (0.53-0.82) Image: Constraint of the terogeneity; l ² = 15.6%	CAPE COVID	NCT02517489	Low: 200 mg/d intravenously	11/75	20/73	0.46 (0.20-1.04)			6.80
Subgroup fixed effect 43/195 51/179 0.69 (0.43-1.12) Methylprednisolone	COVID STEROID	NCT04348305	Low: 200 mg/d intravenously	6/15	2/14	4.00 (0.65-24.66)			1.39
Methylprednisolone Steroids-SARI NCT04244591 High: 40 mg every 12 h intravenously 13/24 13/23 0.91 (0.29-2.87) Overall (fixed effect) 222/678 425/1025 0.66 (0.53-0.82) Image: Comparison of the terogeneity; Image: Comparison of terogeneity; Image	REMAP-CAP	NCT02735707	Low: 50 mg every 6 h intravenously	26/105	29/92	0.71 (0.38-1.33)			11.75
Steroids-SARI NCT04244591 High: 40 mg every 12 h intravenously 13/24 13/23 0.91 (0.29-2.87) Overall (fixed effect) 222/678 425/1025 0.66 (0.53-0.82) Image: Control of the control of th	Subgroup fixed e	ffect		43/195	51/179	0.69 (0.43-1.12)		2	19.94
Overall (fixed effect) 222/678 425/1025 0.66 (0.53-0.82) P = .31 for heterogeneity; I ² = 15.6%	fethylprednisolon	e							
$P = .31$ for heterogeneity; $I^2 = 15.6\%$	Steroids-SARI	NCT04244591	High: 40 mg every 12 h intravenously	13/24	13/23	0.91 (0.29-2.87)			3.46
				222/678	425/1025	0.66 (0.53-0.82)			100.0
Overall (random effects ^a) 222/678 425/1025 0.70 (0.48-1.01)	verall (random ef	fects ^a)		222/678	425/1025	0.70 (0.48-1.01)	\sim		




GENETICS OF MORTALITY IN CRITICAL CARE











Research

JAMA | Original Investigation | CARING FOR THE CRITICALLY ILL PATIENT Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial

The Writing Committee for the REMAP-CAP Investigators

ARTICLE INFORMATION

Accepted for Publication: August 21, 2020. Published Online: September 2, 2020. dol:10.1001/jama.2020.17022

Authors/Writing Committee for REMAP-CAP: Derek C. Angus, MD, MPH; Lennie Derde, MD; Farah Al-Beidh, PhD; Djillall Annane, MD, PhD; Yaseen Arabi, MD; Abigall Beane, MSc; Wilma van Bentum-Puljk, MS; Lindsay Berry, PhD; Zahra Bhimani, MPH, PMP; Marc Bonten, MD; Charlotte Bradbury, MD, PhD; Frank Brunkhorst, MD; Meredith Buxton, PhD; Adrian Buzgau, MSc; Alien C. Cheng, MD; Menno de Jong, MD; Michelie Detry, PhD: Lise Estcourt, MD: Mark Fitzgerald, PhD: Herman Goossens, MD; Cameron Green, MSG Rashan Haniffa, MD; Alisa M. Higgins, PhD; Christopher Horvat, MD, MHA; Sebastiaan J. Hullegie, MD; Peter Kruger, MD; Francols Lamontagne, MD; Patrick R. Lawler, MD; Kelsey Linstrum, MS; Edward Litton, MD; Elizabeth Lorenzi, PhD: John Marshall, MD: Daniel McAuley, MD; Anna McGiothin, PhD; Shay McGuinness, MD; Bryan McVerry, MD; Stephanie Montgomery, MS; Paul Mouncey, MSc; Srinivas Murthy, MD; Alistair Nichol, MD; Rachael Parke, RN, PhD; Jane Parker, RN: Kathryn Rowan, PhD: Ashish Sanii, PhD: Mariene Santos, MSc; Christina Saunders, PhD; Christopher Seymour, MD, MSc; Anne Turner, RN, MPH: Frank van de Veerdonk, MD: Balasubramanian Venkatesh, MD: Ryan Zarychanski, MD; Scott Berry, PhD; Roger J. Lewis, MD. PhD: Colin McArthur, MD: Steven A. Webb, MD, PhD; Anthony C. Gordon, MD.

Affiliations of Authors/Writing Committee for REMAP-CAP: The Clinical Research Investigation and Systems Modeling of Acute Iliness (CRISMA) Center, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (Angus, Horvat, Linstrum, Montgomery, Seymour); The UPMC Health System Office of Healthcare Innovation, Pittsburgh, Pennsylvania (Angus, Horvat, Montgomery, Seymour): Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands (Derde, van Bentum-Puljk, Bonten, Hullegle); Intensive Care Center, University Medical Center Utrecht, Utrecht, the Netherlands (Derde): Division of Anaesthetics. Pain Medicine and Intensive Care Medicine. Department of Surgery and Cancer, Imperial

College London and Imperial College Healthcare NHS Trust, London, United Kingdom (Al-Beidh, Gordon); Intensive Care Unit, Raymond Poincaré Hospital (AP-HP), Paris, France (Annane); Simone Vell School of Medicine, University of Versailles, Versailles, France (Annane); University Paris Saclay, Garches, France (Annane); Intensive Care Department, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center. King Abdulaziz Medical City, Riyadh, Saudi Arabia (Arabi): Nuffleid Department of Clinical Medicine. University of Oxford, Oxford, United Kingdom (Beane); Berry Consultants LLC, Austin, Texas (L. Berry, Detry, Fitzgeraid, Lorenzi, McGlothin, Sanil, Saunders, S. Berry, Lewis); LI Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada (Bhimani, Marshali, Santos); Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands (Bonten): Bristol Royal Informatory, Bristol, United Kingdom (Bradbury); University of Bristol, Bristol, United Kingdom (Bradbury); Center for Clinical Studies and Center for Sepsis Control and Care (CSCC). Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Jena, Germany (Brunkhorst); Global Coalition for Adaptive Research, San Francisco, California (Buxton); Helix, Monash University, Melbourne, Victoria, Australia (Buzgau); Infection Prevention and Healthcare Epidemiology Unit, Alfred Health, Melbourne, Victoria, Australia (Cheng); Australian and New Zealand Intensive Care Research Centre, School of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia (Cheng, Green, Higgins, McGuinness, Nichol, Parker, Webb): Department of Medical Microbiology, Amsterdam University Medical Center, University of Amsterdam, the Netherlands (de Jong); Department of Microbiology, Antwerp University Hospital, Antwerp, Belgium (Goossens); NHS Blood and Transplant, Bristol, United Kingdom (Estcourt); Transfusion Medicine, Medical Sciences Division. University of Oxford, Oxford, United Kingdom (Estcourt): Network for Improving Critical Care Systems and Training, Colombo, Sri Lanka (Haniffa); Mahidol Oxford Tropical Medicine Research Unit. Bangkok, Thailand (Haniffa); Intensive Care Unit, Princess Alexandra Hospital, Brisbane, Queensland, Australia (Kruger); Université de Sherbrooke, Sherbrooke, Quebec, Canada (Lamontagne);

Cardiac Intensive Care Unit, Peter Munk Cardiac Centre, University Health Network. Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada (Lawier): School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia, Australia (Litton, Webb); Interdepartmental Division of Critical Care, University of Toronto, Toronto, Ontario, Canada (Marshall); Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom (McAuley): Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland, New Zealand (McGuinness, Parke): The Health Research Council of New Zealand, Weilington, New Zealand (McGuinness, Parke, Turner); Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (McVerry); Clinical Trials Unit, Intensive Care National Audit & Research Centre (ICNARC), London, United Kingdom (Mouncey, Rowan, McArthur); University of British Columbia School of Medicine, Vancouver, Canada (Murthy); Department of Anesthesia and Intensive Care, St. Vincent's University Hospital, Dublin, Ireland (Nichol); School of Medicine and Medical Sciences, University College Dublin, Dublin, Ireland (Nichol); Department of Intensive Care, Alfred Health, Melbourne, Victoria, Australia (Nichol): School of Nursing, University of Auckland, Auckland, New Zealand (Parke): Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands (van de Veerdonk); Southside Clinical Unit, Princess Alexandra Hospital, Brisbane, Queensland, Australia (Venkatesh): The George Institute for Global Health, Sydney, Australia (Venkatesh); Department of Medicine, Critical Care and Hematology/Medical Oncology, University of Manitoba, Winnipeg, Manitoba, Canada (Zarychanski); Department of Emergency Medicine, Harbor-UCLA Medical Center, Torrance, California (Lewis); Department of Emergency Medicine, David Geffen School of Medicine at University of California, Los Angeles (Lewis): Department of Critical Care Medicine. Auckland City Hospital, Auckland, New Zealand (McArthur); St John of God Hospital, Sublaco, Western Australia, Australia (Webb).

Author Contributions: Dr Angus had full access to all corticosteroid domain data and all baseline data

NIHR National Institute for Health Research



- Hospitals funded to do research
- Central coordination reduces duplication
- Targets established for recruitment to trials

Increasing recruitment into covid-19 trials

An urgent priority for the NHS

Ara Darzi, ¹ Andrew Goddard, ² Katherine Henderson, ³ Ravi Mahajan, ⁴ Clare Marx, ⁵ Neil Mortensen, ⁶ Alison Pittard⁷

Since March 2020, UK researchers have established over 70 urgent public health studies to investigate potential treatments, vaccines, and diagnostic tests for covid-19. NHS hospitals have had a vital role in delivering these studies at pace and scale, despite working under extreme pressure. The results are now informing practice worldwide.

In June 2020, the Recovery trial found that dexamethasone, a widely available corticosteroid, improved survival among covid-19 patients on ventilation by 36% (28 day mortality rate ratio 0.64; variation among hospitals and therefore scope for further improvement.

The largest community based covid-19 trial in the UK, Principle, ⁵⁶ evaluates treatments to prevent hospital admission or transmission, including doxycycline and inhaled budesonide. Recruitment has been slow because of the disruption of primary care during the first wave, reaching 2000 participants in December. To aid recruitment Principle now allows patients to participate remotely regardless of the location of their registered general practitioner.

7-10% of admissions for COVID-19

20% of all ICU admissions

Trials save lives. They cannot do so, however, without the participants on which they depend. Recruitment of patients with covid-19 to UK clinical trials must now be prioritised. Although vaccines against

COVID-19 is Changing Clinical Research

- New trial designs
- International collaboration
- Acceptance of research as integral to clinical care
- Embedding of research into the provision of excellent clinical care



Thank you!